EODData

FRA, 978: ADAGENE INC. SP.ADR

26 Mar 2026
LAST:

3.520

CHANGE:
 0.26
OPEN:
3.380
HIGH:
3.520
ASK:
0.000
VOLUME:
622
CHG(%):
7.98
PREV:
3.260
LOW:
3.360
BID:
0.000
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Mar 263.3803.5203.3603.520622
25 Mar 263.0203.2603.0203.260622
24 Mar 263.3403.3403.1603.160622
23 Mar 263.0203.0402.9802.980622
20 Mar 263.1603.1603.1003.100622
19 Mar 263.3603.3603.2003.2000
18 Mar 263.3603.3603.3603.3600
17 Mar 263.3603.3603.2203.2200
16 Mar 263.4603.6203.4603.6200
13 Mar 262.9803.2402.9803.2400

PROFILE

Name:ADAGENE INC. SP.ADR
About:Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Sector:Healthcare
Industry:Biotechnology
Address:Building C14, Suzhou, China, 215123
Website:https://www.adagene.com
ISIN:US0053291078

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:-1.98 
Forward P/E:-0.67 
PEG Ratio:-0.67 
Price to Sales:674.77 
Price to Book:1.82 
Operating Margin:-322.84 
Return on Assets:-0.25 
Return on Equity:-0.63 
Revenue:89.6K 
Shares:47.13M 
Market Cap:165.9M 

TECHNICAL INDICATORS

MA5:3.209.9%
MA10:3.277.8%
MA20:2.9220.7%
MA50:2.0670.7%
MA100:1.8194.2%
MA200:1.73103.5%
STO9:84.38 
STO14:91.80 
RSI14:68.84 
WPR14:-8.20 
MTM14:1.12
ROC14:0.47 
ATR:0.24 
Week High:3.520.0%
Week Low:2.9818.1%
Month High:3.622.8%
Month Low:2.34103.5%
Year High:3.622.8%
Year Low:1.19196.0%
Volatility:8.38